FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Mon 20:00
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports June 29 (Reuters) - The U.S. Food and Drug Administration has selected Eli Lilly LLY.N and Regeneron REGN.O, among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC reported on Monday citing an FDA spokesperson.
(Reporting by Puyaan Singh in Bengaluru; Editing by Sahal Muhammed)
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)